When ‘Made in India’ really means ‘Made in China’
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- NITI Aayog's June 2026 Trade Watch Quarterly report found India's pharma industry relies on China for over 65% of key starting materials and active pharmaceutical ingredients, with dependency exceeding 85% for entire drug classes including antibiotics and fever reducers
- India produces 20% of the world's generic drugs by volume and supplies 60% of global vaccine doses, yet captures only 0.6% of the global vaccine market by value — supplying the bulk of the world's immunity for less than a penny per dollar of revenue
- Indian pharmaceutical companies invest around 7% of revenues in R&D, compared to 15-20% at top international pharma companies, while India's slow patent approval process and bureaucratic inertia steer firms toward copying drugs over developing new ones
- Zero Liquid Discharge environmental regulations have inflated costs so severely that 35-40% of R&D expenses at some API operations now go to wastewater management and environmental approvals rather than science, driving manufacturers to import cheaper, regulation-free Chinese ingredients
- NITI Aayog Vice Chairman Ashok Kumar Lahiri said the sector needs to "move up the value chain," noting the industry remains trapped in low-margin generics as global pharma advances into biologics, cell and gene therapies, and immunologics
- India's post-2020 border tensions restrictions on Chinese investment and technology have not reduced dependence but made it more opaque, the report shows, while Western capitals simultaneously deepened their own trade deals with China, securing their own supply chains
- The Modi government's "Made in India" economic nationalism is directly challenged by the data: India's export strength in pharma masks structural reliance on Chinese raw materials that a single Chinese port lockdown could sever
Why it matters: Modi's "Made in India" economic nationalism is structurally hollow in its most celebrated sector: a single Chinese port shutdown would cut off antibiotics and fever reducers that India provides to developing nations worldwide, exposing how the "Pharmacy of the World" title is propped up by a tenuous Chinese chemical pipeline. India supplies 60% of global vaccine doses by volume but captures just 0.6% of the market by value — an unsustainable industrial policy that effectively subsidizes global public health at domestic expense.
Ask SkimNews
